GlassScriptPhysician profile
Richard J Schumann
NPI 1831157916
$18,780.19
in general payments reported to CMS, 2019-2025
53 companies · $2,383 in 2025
The $2,383 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,966 · 2020: $1,128 · 2021: $3,758 · 2022: $4,652 · 2023: $2,475 · 2024: $2,419 · 2025: $2,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,473 · Travel and Lodging: $1,640 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,472.54 |
| Travel and Lodging | $1,639.85 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,217.78 | 2023-2025 | Inspire |
| Harmony Biosciences LLC | $1,690.90 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $1,521.19 | 2019-2025 | Xywav |
| Abbvie INC. | $1,332.30 | 2021-2025 | Ubrelvy, Botox |
| Lilly USA, LLC | $966.23 | 2019-2025 | Zepbound, Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $894.05 | 2021 | |
| Emd Serono, INC. | $850.16 | 2019-2023 | Mavenclad |
| Biohaven Pharmaceutical Holding Company LTD. | $800.27 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $692.67 | 2019-2024 | Austedo, Ajovy |
| Ucb, INC. | $551.03 | 2019-2023 | Briviact |
| Allergan, INC. | $523.25 | 2020-2022 | |
| Biogen, INC. | $497.76 | 2019-2023 | Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $446.10 | 2019-2023 | |
| Amgen INC. | $405.60 | 2019-2022 | |
| Zoll Respicardia, INC. | $398.73 | 2019-2025 | Remede System |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Schumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.